Bavachin
Based on 13 publication(s) in Google Scholar
Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC50s of 320 and 680 nM, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 19879-32-4
- Formule: C20H20O4
- Masse moléculaire:324.37
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Phenols Library
HY-L057
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Nuclear Receptor Compound Library
HY-L126
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Bavachin
More- Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
- Food Chem. 2025 Dec 30:497:146992. [Abstract]
- Food Chem. 2025 May 31:489:144992. [Abstract]
- Mol Med. 2026 Feb 28;32(1):32. [Abstract]
- Mol Med. 2025 Jun 11;31(1):234. [Abstract]
- J Ethnopharmacol. 2022 Nov 15:298:115593. [Abstract]
- Int J Mol Sci. 2026 Feb 5;27(3):1576. [Abstract]
- Chem Biol Interact. 2024 Jul 3:111133. [Abstract]
- Genomics. 2021 Jul;113(4):2702-2716. [Abstract]
- J Cancer. 2025 Mar 31;16(7):2339-2352. [Abstract]
- bioRxiv. 2025 Jan 03.
- Oxid Med Cell Longev. 2021 Oct 18:2021:1783485. [Abstract]
- Front Med. 2021 Aug;15(4):594-607. [Abstract]
Customer Validation & Images
-
Histological Imaging/Staining
-
WB
-
IF
-
IHC
Activité biologique
IC50: 320 nM (ERα), 680 nM (ERβ)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 10
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| A549 | IC50 |
30.5 μM
Compound: 1
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 29335212] |
| HCT-116 | IC50 |
20.7 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 29335212] |
| K562 | IC50 |
>10 μM
Compound: 10
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| MCF7 | IC50 |
19.5 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 29335212] |
| PC-3 | IC50 |
25.4 μM
Compound: 1
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 29335212] |
Bavachin significantly inhibits melanin synthesis and TYR activity. Bavachin (10 μM) inhibits the expression of TYR and JNK proteins, and the expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2 mRNA in A375 cells. ICI182780 and U0126 cAN significantly reverse the bavachin treatment on the protein expression levels and the mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2 and JNK2[1]. Bavachin accumulates lipid in a dose dependent manner in ORO staining experiments. Bavachin significantly increases the growth of preadipoctye at 10 μM compared with the control cells in MTT assay. Bavachin also increases BrdU incorporation into newly synthesized DNA during pre-adipocyte proliferation. BrdU incorporation is enhanced by insulin and further enhanced by co-treatment with insulin and bavachin at 2 and 10 μM. Bavachin activates adipogenic factors and increases PPARγ transcriptional activity in differentiated adipocytes. Bavachin enhances insulin-stimulated glucose uptake through GLUT4 translocation via Akt and AMPK pathway[2]. BVN significantly increases both hMAO-A and hMAO-B activities[3]. Bavachin shows ER ligand binding activity in competitive displacement of [3H] E2 from recombinant ER. The estrogenic activity of bavachin is characterized in a transient transfection system using ERα or ERβ and estrogen-responsive luciferase plasmids in CV-1 cells with an EC50 of 320 nM and 680 nM, respectively. Bavachin increases the mRNA levels of estrogen-responsive genes such as pS2 and PR, and decreases the protein level of ERα by proteasomal pathway[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 19879-32-4
-
Appearance Solid
-
Masse moléculaire 324.37
-
Formule C20H20O4
-
Color White to light yellow
-
SMILES
O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=CC(O)=C(C/C=C(C)\C)C=C13
-
Synonyms
Corylifolin
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]2021 Jan;11(1):143-155. PMID: 33532186 -
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 May 31:489:144992. PMID: 40466530 -
Mol Med
Correction: Bavachin ameliorates cisplatin-induced nephrotoxicity by enhancing mitochondrial β-oxidation and lipid metabolism through MFN2. [Abstract]2026 Feb 28;32(1):32. PMID: 41764431 -
Mol Med
Bavachin ameliorates cisplatin-induced nephrotoxicity by enhancing mitochondrial β-oxidation and lipid metabolism through MFN2. [Abstract]2025 Jun 11;31(1):234. PMID: 40500698
Bavachin purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 11;31(1):234. [Abstract]
Representative images of hematoxylin and eosin staining treated with Bavachin (10 mg/kg, p.o.).
Bavachin purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 11;31(1):234. [Abstract]
Representative western blotting analysis of KIM-1 and NGAL protein levels in mouse kidneys treated with Bavachin (10 mg/kg, p.o.).
Bavachin purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 11;31(1):234. [Abstract]
Representative image of DHE staining treated with Bavachin (10 mg/kg, p.o.).
Bavachin purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 11;31(1):234. [Abstract]
Representative images of immunohistochemical staining of MFN2 in renal tissues from each group treated with Bavachin (10 mg/kg, p.o.).
-
J Ethnopharmacol
2022 Nov 15:298:115593. PMID: 35973629 -
Int J Mol Sci
Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade. [Abstract]2026 Feb 5;27(3):1576. PMID: 41683994 -
Chem Biol Interact
Bavachinin, a main compound of Psoraleae Fructus, facilitates GSDMD-mediated pyroptosis and causes hepatotoxicity in mice. [Abstract]2024 Jul 3:111133. PMID: 38969277 -
Genomics
Transcriptomics and metabolomics reveal the induction of flavonoid biosynthesis pathway in the interaction of Stylosanthes-Colletotrichum gloeosporioides. [Abstract]2021 Jul;113(4):2702-2716. PMID: 34111523 -
J Cancer
Bavachin suppresses proliferation of laryngopharyngeal cancer by regulating the STAT3 and MAPK signaling pathways. [Abstract]2025 Mar 31;16(7):2339-2352. PMID: 40302804 -
-
Oxid Med Cell Longev
2021 Oct 18:2021:1783485. PMID: 34707773 -
Front Med
Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity. [Abstract]2021 Aug;15(4):594-607. PMID: 33909257
Solvant et solubilité
DMSO : 100 mg/mL (308.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
The chemiluminescent assay is used to confirm PCSEE MAO-A and MAO-B inhibitory effects and to test BNN and BVN hMAO-A and hMAO-B inhibition using MAO-Glo kit. Each enzyme's Arbitrary Light Unit (ALU) is measured in the presence of PCSEE, BNN, BVN, and standard DEP as an MAO-BI positive control. Briefly, hMAO-A and hMAO-B isozymes are diluted to 2× with reaction buffer (pH 7.4) and preincubated with 4× PCSEE, BNN, BVN, or DEP working solutions at RT for 30 min in white opaque 96-well plates. For determining activity inhibition, final 8.5 μg/mL concentrations of PCSEE, BNN, BVN, and DEP are used. For IC50 determination, 8× PCSEE and BNN working solutions are serially diluted using reaction buffers (pH 7.4) to make a 4× concentration. Ten points' range of PCSEE (1.0 to 250.0 μg/mL) and BNN (up to 400 μM (135.4 μg/mL)) final concentrations is used. Controls used are with and without ethanol. Ethanol solvent in controls is kept to a maximum final (volume) of ≤2%. Each isozyme is substituted with the reaction buffer for the blank. Based on our preliminary optimizations and Valley's method, the reaction is initiated by adding 4× luciferin derivative substrate (LDS) for a final (concentration) of 40 and 4 μM for hMAO-A and hMAO-B reactions, respectively. The final volume per well of each reaction is 50 μL. The reaction is optimized for the amount of A and B enzyme used to be incubated for less than 3.5 h at RT. To stop the reaction and produce the luminescence signal RLDR is added to all wells, 50 μL to each well, and incubated for a further 30 min.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MTT solution (20 µL) is added to each well of the 96-well plates, the cells are cultured for 4 h, the solution is discarded, and the purple crystal is dissolved in the wells with 150 µL DMSO solution, agitated in a 37°C incubator shaker for 10 min, and the optical density (OD) is measured at 490 nm by the microplate reader.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wang JH, et al. Effects of bavachin and its regulation of melanin synthesis in A375 cells. Biomed Rep. 2016 Jul;5(1):87-92. Epub 2016 May 20. [Content Brief]
[2]. Lee H, et al. Bavachin from Psoralea corylifolia Improves Insulin-Dependent Glucose Uptake through Insulin Signaling and AMPK Activation in 3T3-L1 Adipocytes. Int J Mol Sci. 2016 Apr 8;17(4):527 [Content Brief]
[3]. Zarmouh NO, et al. Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B. Evid Based Complement Alternat Med. 2015;2015:852194 [Content Brief]
[4]. Park J, et al. Activation of Estrogen Receptor by Bavachin from Psoralea corylifolia. Biomol Ther (Seoul). 2012 Mar;20(2):183-8 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0829 mL | 15.4145 mL | 30.8290 mL | 77.0725 mL |
| 5 mM | 0.6166 mL | 3.0829 mL | 6.1658 mL | 15.4145 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0829 mL | 7.7072 mL | |
| 15 mM | 0.2055 mL | 1.0276 mL | 2.0553 mL | 5.1382 mL | |
| 20 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL | 3.8536 mL | |
| 25 mM | 0.1233 mL | 0.6166 mL | 1.2332 mL | 3.0829 mL | |
| 30 mM | 0.1028 mL | 0.5138 mL | 1.0276 mL | 2.5691 mL | |
| 40 mM | 0.0771 mL | 0.3854 mL | 0.7707 mL | 1.9268 mL | |
| 50 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5414 mL | |
| 60 mM | 0.0514 mL | 0.2569 mL | 0.5138 mL | 1.2845 mL | |
| 80 mM | 0.0385 mL | 0.1927 mL | 0.3854 mL | 0.9634 mL | |
| 100 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.7707 mL |
Bavachin Related Classifications
HY-N0233 Related Classifications
Powered by Bioz